Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Synergy Chc Corp. Common Stock
Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability
Business
Aug 14 2025
11 min read

Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

news images

WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three months ended June 30, 2025.

“We are pleased to report another strong quarter, marking our tenth consecutive quarter of profitability,” said Jack Ross, CEO of Synergy. “Revenue, gross profit, net income and earnings per share all grew year-over-year, reflecting our continued focus on disciplined execution and profitable growth.”

“We also made significant progress across our strategic priorities, including expanding the global footprint of our FOCUSfactor brand through a licensing agreement in Turkey. On the beverage side, our new leadership team is already driving results, securing distribution partners across North America and advancing the growth of our RTD business. In addition, we successfully completed a $20 million debt refinancing, which is a significant milestone for the company. It extends our maturity profile, enhances financial flexibility and supports our long-term growth strategy. With this improved capital structure and continued momentum, we’re well positioned to accelerate growth in the second half of 2025 and beyond.”

Second Quarter 2025 Financial Summary vs. Same Year-Ago Period

  • Revenue of $8.1 million vs. $8.0 million.

  • Gross margin of 76.7% vs. 69.5%.

  • Income from operations of $1.62 million vs. $1.58 million.

  • Net income of $1.5 million vs. $655.2 thousand.

  • Earnings per share of $0.17 vs. $0.09.

  • EBITDA, a non-GAAP financial measure, was $3.80 million vs. $1.61 million.

Recent Business Highlights

  • Synergy recently announced a series of major North American retail and distribution wins across its FOCUSfactor supplement and beverage lines, significantly expanding availability across mass, grocery, pharmacy, convenience and wholesale channels, which should start yielding significant results in the fourth quarter of 2025.

  • On June 18, 2025, Synergy announced the expansion of its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates (UAE) for exclusive distribution of FOCUSfactor.

  • On June 4, 2025, Synergy announced that it entered into a $20 million term loan credit agreement, due May 2029, with ACP Agency, LLC, of which $17.5 million has been drawn.

  • During the second quarter, Synergy announced the additions of key individuals to drive the Company’s beverage growth.

  • During the second quarter, the Company reduced outstanding liabilities by $869 thousand.

  • Subsequent to the quarter end, Synergy reduced outstanding notes payable by $1.8 million.

Second Quarter 2025 Financial Results

Revenue in the second quarter of 2025 was $8.1 million, up 1% compared to $8.0 million in the second quarter of 2024. The Company generated $1.4 million in license revenue during the quarter.

Gross margin in the second quarter of 2025 was 76.7% compared to 69.5% in the second quarter of 2024. The increase was largely driven by license revenue.

Operating expenses in the second quarter of 2025 were $4.6 million, up 16% compared to $4.0 million in the second quarter of 2024. The increase was driven by incremental costs associated with being a public company.

Income from operations for the second quarter of 2025 was $1.62 million, up 2.5% compared to $1.58 million in the second quarter of 2024. The increase in operating income was due to the improvement in gross margin.

Net income in the second quarter of 2025 was $1.5 million, up 125% compared to net income of $655.2 thousand in the second quarter of 2024.

Earnings per share in the second quarter was $0.17, up 86% compared to $0.09 in the second quarter of 2024.

EBITDA (a non-GAAP financial measure) in the second quarter of 2025 was $3.80 million, up 136% compared to $1.61 million in the second quarter of 2024.

Balance Sheet and Cash Flow

As of June 30, 2025, Synergy had approximately $1.5 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024.

As of June 30, 2025, Synergy had a working capital surplus of $12.4 million, compared to a $1.12 million working capital deficit as of December 31, 2024.

As of June 30, 2025, Synergy had $2.4 million in inventory, compared to $1.7 million in inventory as of December 31, 2024.

Cash used in operating activities for the six months ended June 30, 2025 was $899.7 thousand compared to cash used in operating activities of $1.1 million for the six months ended June 30, 2024.

Non-GAAP Financial Measure Reconciliation: EBITDA

To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

Management believes EBITDA provides useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization.

The following table reconciles net income to EBITDA (in millions of US dollars):

 

 

 

 

 

 

3 Months ended June 30

 

2025

2024

 

 

 

Net income for the period

$1.47

$0.66

Adjusted for:

 

 

Interest expense, net

2.11

0.74

Amortization of intangible assets

0.03

0.03

Tax expense

0.19

0.18

EBITDA

$3.80

$1.61


Conference Call

In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2025 with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

About Synergy CHC Corp.

Synergy CHC Corp. is a provider of consumer health and wellness products. Its brand portfolio includes two flagship names: FOCUSfactor, a clinically studied brain health supplement shown to improve memory, concentration, and focus; and Flat Tummy, a lifestyle brand offering nutritional solutions designed to support women's wellness and weight management goals.

Forward Looking Statements

Certain statements contained in this press release constitute "forward-looking statements," including statements regarding expansion and growth initiatives, refinancing of our indebtedness and our free cash flow. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group
Cody Slach, Greg Robles
949.574.3860
SNYR@gateway-grp.com

Synergy CHC Corp.

Condensed Consolidated Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

June 30,

 

 

December 31,

 

2025

2024

 

 

(unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,458,561

 

 

$

687,920

 

Restricted cash

 

 

100,000

 

 

 

100,000

 

Accounts receivable, net

 

 

7,069,889

 

 

 

5,321,037

 

Other receivables

 

 

2,025,094

 

 

 

1,999,637

 

Loan receivable (related party)

 

 

4,427,883

 

 

 

4,375,059

 

Prepaid expenses (including related party amount of $801,345 and $312,966, respectively)

 

 

2,064,094

 

 

 

1,859,563

 

Inventory, net

 

 

2,364,158

 

 

 

1,716,552

 

Total Current Assets

 

 

19,509,679

 

 

 

16,059,768

 

 

 

 

 

 

 

 

 

 

Intangible assets, net

 

 

216,667

 

 

 

283,333

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$

19,726,346

 

 

$

16,343,101

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities (including payable to shareholder of $92,955 and $88,644, respectively)

 

$

4,960,331

 

 

$

5,191,868

 

Income taxes payable

 

 

266,472

 

 

 

242,977

 

Contract liabilities

 

 

4,887

 

 

 

24,252

 

Short term loans payable, net of debt discount

 

 

1,894,857

 

 

 

7,725,272

 

Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder

 

 

-

 

 

 

4,000,000

 

Total Current Liabilities

 

 

7,126,547

 

 

 

17,184,369

 

 

 

 

 

 

 

 

 

 

Long-term Liabilities:

 

 

 

 

 

 

 

 

Notes payable, net of debt discount, shareholder

 

 

-

 

 

 

8,333,053

 

Notes payable, net of debt discount

 

 

24,978,999

 

 

 

7,457,022

 

Total long-term liabilities

 

 

24,978,999

 

 

 

15,790,075

 

Total Liabilities

 

 

32,105,546

 

 

 

32,974,444

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ Deficit:

 

 

 

 

 

 

 

 

Common stock, $0.00001 par value; 300,000,000 shares authorized; 9,621,926 and 8,721,818, shares issued, respectively; 9,441,853 and 8,541,745 outstanding, respectively

 

 

96

 

 

 

87

 

Additional paid in capital

 

 

29,508,354

 

 

 

27,643,660

 

Accumulated other comprehensive loss

 

 

(9,838

)

 

 

(47,777

)

Accumulated deficit

 

 

(41,750,312

)

 

 

(44,099,813

)

Less: Treasury stock (180,073 shares) at cost

 

 

(127,500

)

 

 

(127,500

)

Total stockholders’ deficit

 

 

(12,379,200

)

 

 

(16,631,343

)

Total Liabilities and Stockholders’ Deficit

 

$

19,726,346

 

 

$

16,343,101

 

 

 

 

 

 

 

 

 

 


Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Income and Comprehensive Income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the three months ended

 

 

For the six months ended

 

 

 

June 30,

 

 

June 30,

 

 

June 30,

 

 

June 30,

 

2025

2024

2025

2024

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Product Sales

 

$

6,734,996

 

 

$

8,024,840

 

 

$

13,405,530

 

 

$

17,436,703

 

License Revenue

 

 

1,400,000

 

 

 

-

 

 

 

2,900,000

 

 

 

-

 

Total Revenue

 

 

8,134,996

 

 

 

8,024,840

 

 

 

16,305,530

 

 

 

17,436,703

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

 

1,896,391

 

 

 

2,448,890

 

 

 

3,902,904

 

 

 

5,086,029

 

Gross profit

 

 

6,238,605

 

 

 

5,575,950

 

 

 

12,402,626

 

 

 

12,350,674

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling and marketing

 

 

3,062,211

 

 

 

3,055,186

 

 

 

5,938,482

 

 

 

6,639,863

 

General and administrative

 

 

1,519,325

 

 

 

903,838

 

 

 

2,826,039

 

 

 

2,252,223

 

Depreciation and amortization

 

 

33,334

 

 

 

33,334

 

 

 

66,667

 

 

 

66,667

 

Total operating expenses

 

 

4,614,870

 

 

 

3,992,358

 

 

 

8,831,188

 

 

 

8,958,753

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from operations

 

 

1,623,735

 

 

 

1,583,592

 

 

 

3,571,438

 

 

 

3,391,921

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

(379

)

 

 

(374

)

 

 

(14,261

)

 

 

(761

)

Interest expense

 

 

2,107,714

 

 

 

745,528

 

 

 

3,203,083

 

 

 

1,855,508

 

Gain on settlement of notes payable

 

 

(2,154,522

)

 

 

-

 

 

 

(2,154,522

)

 

 

-

 

Remeasurement (gain) loss on translation of foreign subsidiary

 

 

7,578

 

 

 

3,870

 

 

 

8,990

 

 

 

(5,113

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total other (income) expenses

 

 

(39,609

)

 

 

749,024

 

 

 

1,043,290

 

 

 

1,849,634

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income before income taxes

 

 

1,663,344

 

 

 

834,568

 

 

 

2,528,148

 

 

 

1,542,287

 

Income tax benefit (expense)

 

 

(190,107

)

 

 

(179,382

)

 

 

(178,647

)

 

 

(306,571

)

Net income after tax

 

$

1,473,237

 

 

$

655,186

 

 

$

2,349,501

 

 

$

1,235,716

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share – basic

 

$

0.17

 

 

$

0.09

 

 

$

0.27

 

 

$

0.17

 

Net income per share – diluted

 

$

0.17

 

 

$

0.09

 

 

$

0.27

 

 

$

0.17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

8,928,548

 

 

 

7,373,745

 

 

 

8,743,639

 

 

 

7,373,745

 

Diluted

 

 

8,928,548

 

 

 

7,373,745

 

 

 

8,743,639

 

 

 

7,373,745

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

1,473,237

 

 

 

655,186

 

 

 

2,349,501

 

 

 

1,235,716

 

Foreign currency translation adjustment

 

 

39,874

 

 

 

55,736

 

 

 

37,939

 

 

 

187,373

 

Comprehensive income

 

$

1,513,111

 

 

$

710,922

 

 

$

2,387,440

 

 

$

1,423,089

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Cash Flows

 

 

 

 

 

 

 

 

 

 

 

For the six

 

 

For the six

 

months ended

months ended

 

 

 

June 30,

 

 

June 30,

 

2025

2024

Cash Flows from Operating Activities

 

 

 

 

 

 

Net income

 

$

2,349,501

 

 

$

1,235,716

 

Adjustments to reconcile net income to net cash used in operating activities:

 

 

 

 

 

 

 

 

Amortization of debt discount and debt issuance cost

 

 

892,435

 

 

 

-

 

Depreciation and amortization

 

 

66,667

 

 

 

66,667

 

Stock based compensation

 

 

-

 

 

 

4,611

 

Stock issued for modification of notes payable

 

 

847,062

 

 

 

-

 

Foreign currency transaction loss (gain)

 

 

(9,068

)

 

 

23,345

 

Remeasurement loss (gain) on translation of foreign subsidiary

 

 

8,990

 

 

 

(5,113

)

Non cash implied interest

 

 

-

 

 

 

4,799

 

Gain on settlement of debt

 

 

(2,154,522

)

 

 

-

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(1,748,852

)

 

 

(1,161,992

)

Other receivables

 

 

(25,457

)

 

 

-

 

Loan receivable, related party

 

 

(52,824

)

 

 

35,449

 

Inventory

 

 

(647,606

)

 

 

1,805,950

 

Prepaid expenses

 

 

283,848

 

 

 

(276,818

)

Prepaid expense, related party

 

 

(488,379

)

 

 

(326,682

)

Income taxes payable

 

 

23,495

 

 

 

262,374

 

Contract liabilities

 

 

(19,365

)

 

 

(2,949

)

Accounts payable and accrued liabilities

 

 

(610,770

)

 

 

(2,804,381

)

Accounts payable, shareholder

 

 

385,114

 

 

 

(980

)

Net cash used in operating activities

 

 

(899,731

)

 

 

(1,140,005

)

 

 

 

 

 

 

 

 

 

Cash Flows from Investing Activities

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

Advances from related party

 

 

135,000

 

 

 

1,509,226

 

Repayment of notes payable, related party

 

 

(135,000

)

 

 

(84,500

)

Proceeds from notes payable

 

 

18,996,250

 

 

 

600,000

 

Payment of loan financing fees

 

 

(1,980,914

)

 

 

-

 

Repayment of notes payable, shareholder

 

 

(10,000,000

)

 

 

-

 

Repayment of notes payable

 

 

(5,382,903

)

 

 

(1,617,335

)

Net cash provided by financing activities

 

 

1,632,433

 

 

 

407,391

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate on cash, cash equivalents and restricted cash

 

 

37,939

 

 

 

187,373

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

770,641

 

 

 

(545,241

)

 

 

 

 

 

 

 

 

 

Cash and restricted cash, beginning of year

 

 

787,920

 

 

 

732,534

 

Cash and restricted cash, end of period

 

$

1,558,561

 

 

$

187,293

 

 

 

 

 

 

 

 

 

 

Supplemental Disclosure of Cash Flow Information:

 

 

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

 

 

 

Interest

 

$

896,734

 

 

$

1,850,896

 

Income taxes

 

$

-

 

 

$

44,197

 

 

 

 

 

 

 

 

 

 

Supplemental Disclosure of Noncash Investing and Financing Activities:

 

 

 

 

 

 

 

 

Accounts payable converted to loan payable upon settlement

 

$

-

 

 

$

3,770,824

 

Reduction of short term related party note payable by reduction of prepaid balance

 

$

-

 

 

$

328,003

 

Issuance of common stock for loan financing

 

$

117,648

 

 

$

-

 

Issuance of pre-funded warrants for settlement of shareholder notes payable

 

$

899,993

 

 

$

-

 

Exercise of pre-funded warrants

 

$

4

 

 

$

-

 

Loan fees payable to lender

 

$

375,000

 

 

$

-